Human Genome Epidemiology Literature Finder
Records 1 - 30 (of 47 Records) |
Query Trace: Neoplasms and RRM1[original query] |
---|
Gemcitabine metabolic pathway genetic polymorphisms and response in patients with non-small cell lung cancer. Pharmacogenetics and genomics 2012 Feb 22 (2): 105-16. Li Liang, Schaid Daniel J, Fridley Brooke L, Kalari Krishna R, Jenkins Gregory D, Abo Ryan P, Batzler Anthony, Moon Irene, Pelleymounter Linda, Eckloff Bruce W, Wieben Eric D, Sun Zhifu, Yang Ping, Wang Liew |
Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2012 Jun 7 (6): 973-81. Liao Wei-Yu, Shih Jin-Yuan, Chang Gee-Chen, Cheng Yu-Kai, Yang James Chih-Hsin, Chen Yuh-Min, Yu Chong-J |
Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinoma. Cancer 2012 Nov 118 (22): 5588-94. Ren Shengxiang, Chen Xiaoxia, Kuang Peng, Zheng Limou, Su Chunxia, Li Jiayu, Li Bing, Wang Yongshen, Liu Lu, Hu Qiong, Zhang Jie, Tang Liang, Li Xuefei, Zhou Caicun, Schmid-Bindert Gera |
Association between single nucleotide polymorphisms (SNPs) and toxicity of advanced non-small-cell lung cancer patients treated with chemotherapy. PloS one 2012 7 (10): e48350. Zhang Ling, Gao Guanghui, Li Xuefei, Ren Shengxiang, Li Aiwu, Xu Jianfang, Zhang Jie, Zhou Caic |
Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer. Lung cancer (Amsterdam, Netherlands) 2013 Nov 82 (2): 288-93. Mazzoni Francesca, Cecere Fabiana Letizia, Meoni Giulia, Giuliani Costanza, Boni Luca, Camerini Andrea, Lucchesi Sara, Martella Francesca, Amoroso Domenico, Lucherini Elisa, Torricelli Francesca, Di Costanzo Frances |
RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients. Pharmacogenomics 2013 Sep 14 (12): 1449-66. Cao Xueyuan, Mitra Amit K, Pounds Stanley, Crews Kristine R, Gandhi Varsha, Plunkett William, Dolan M Eileen, Hartford Christine, Raimondi Susana, Campana Dario, Downing James, Rubnitz Jeffrey E, Ribeiro Raul C, Lamba Jatinder |
Predictive value of ERCC1 and RRM1 gene single-nucleotide polymorphisms for first-line platinum- and gemcitabine-based chemotherapy in non-small cell lung cancer patients. Oncology reports 2013 Nov 30 (5): 2385-98. Mlak Rados?aw, Krawczyk Pawe?, Ramlau Rodryg, Kalinka-Warzocha Ewa, Wasylecka-Morawiec Maja, Wojas-Krawczyk Kamila, Kucharczyk Tomasz, Homa Iwona, Kozio? Piotr, Ciesielka Marzanna, Chudziak Dorota, Milanowski Janu |
Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy. European journal of cancer (Oxford, England : 1990) 2014 Mar 50 (4): 698-705. Lee Soo-Youn, Im Seock-Ah, Park Yeon Hee, Woo Sook Young, Kim Seonwoo, Choi Moon Ki, Chang Wonjin, Ahn Jin Seok, Im Young-Hyu |
Mutations of EGFR or KRAS and expression of chemotherapy-related genes based on small biopsy samples in stage IIIB and IV inoperable non-small cell lung cancer. Journal of cancer research and clinical oncology 2014 Dec 140 (12): 2097-105. Deng Li-Li, Deng Hong-Bin, Lu Chang-Lian, Guo Yang, Wang Di, Yan Chun-Hua, Lv Xing, Shao Yu-X |
Association of novel gene polymorphisms RRM1 -756T>C and -269 C>A with breast cancer. Journal of clinical laboratory analysis 2014 Jul 28 (4): 287-93. Chen Dar-Ren, Chuang Chun-Yi, Wu Buor-Chang, Yang Shun-Fa, Peng Yu-Hsien, Tsai Hsiu-Ti |
The relationship between polymorphisms of genes regulating DNA repair or cell division and the toxicity of platinum and vinorelbine chemotherapy in advanced NSCLC patients. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2015 Jul . Powrózek T, Mlak R, Krawczyk P, Homa I, Ciesielka M, Kozio? P, Prendecka M, Milanowski J, Ma?ecka-Massalska |
Association of GSTP1 and RRM1 Polymorphisms with the Response and Toxicity of Gemcitabine-cisplatin Combination Chemotherapy in Chinese Patients with Non-small Cell Lung Cancer. Asian Pacific journal of cancer prevention : APJCP 2015 16 (10): 4347-51. Yuan Zhi-Jun, Zhou Wen-Wu, Liu Wei, Wu Bai-Ping, Zhao Jin, Wu Wei, He Yi, Yang Shuo, Su Jing, Luo |
A Survival Association Study of 102 Polymorphisms Previously Associated with Survival Outcomes in Colorectal Cancer. BioMed research international 2015 2015 968743. Savas Sevtap, Xu Jingxiong, Werdyani Salem, Shestopaloff Konstantin, Dicks Elizabeth, Green Jane, Parfrey Patrick, Green Roger, Xu W |
Association between epidermal growth factor receptor mutations and the expression of excision repair cross-complementing protein 1 and ribonucleotide reductase subunit M1 mRNA in patients with non-small cell lung cancer. Experimental and therapeutic medicine 2015 Mar 9 (3): 880-884. Xu Chun-Wei, Wang Gang, Wang Wu-Long, Gao Wen-Bin, Han Chuan-Jun, Gao Jing-Shan, Li Yang, Wang Lin, Zhang Li-Ying, Zhang Yu-Ping, Tian Yu-Wang, Fang Jin- |
The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2015 Dec . Mlak R, Krawczyk P, Ciesielka M, Kozio? P, Homa I, Powrózek T, Prendecka M, Milanowski J, Ma?ecka-Massalska |
Predicting chemosensitivity to gemcitabine and cisplatin based on gene polymorphisms and mRNA expression in non-small-cell lung cancer cells. Pharmacogenomics 2015 1 16 (1): 23-34. Meng Xiangning, Wang Geng, Guan Rongwei, Jia Xueyuan, Gao Wei, Wu Jie, Yu Jingcui, Liu Peng, Yu Yang, Sun Wenjing, Dong Haiying, Fu Songb |
Polymorphisms in cancer-related pathway genes and lung cancer. The European respiratory journal 2016 Sep . Lee Shin Yup, Kang Hyo-Gyoung, Choi Jin Eun, Jung Deuk Kju, Lee Won Kee, Lee Hyun Chul, Lee So Yeon, Yoo Seung Soo, Lee Jaehee, Seok Yangki, Lee Eung Bae, Cha Seung Ick, Cho Sukki, Kim Chang Ho, Lee Myung Hoon, Park Jae Yo |
RRM1 *151A>T, RRM1 -756T>C, and RRM1 -585T>Gis associated with increased susceptibility of lung cancer in Chinese patients. Cancer medicine 2016 Jun . Xu Xiao-Ling, Zheng Ji, Mao Wei-Min, Ling Zhi-Qia |
Association of the Genetic Polymorphisms RRM1 -756T>C and -269C>A With Cervical Neoplasia. Biological research for nursing 2016 May . Chang Ching-Wen, Yang Shun-Fa, Wang Po-Hui, Chang Hsiu-Ju, Liu Wen-Chi, Tsai Hsiu-Ti |
Combined analysis of rearrangement of ALK, ROS1, somatic mutation of EGFR, KRAS, BRAF, PIK3CA, and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR in patients with non-small cell lung cancer and their clinical significance. Cancer chemotherapy and pharmacology 2016 Mar 77 (3): 583-93. Zhang Quan, Sun Tianyu, Kang Poming, Qian Kai, Deng Bo, Zhou Jinghai, Wang Ruwen, Jiang Bin, Li Kun, Liu Fang, Wu Shiyang, Tan Quny |
Evaluation of Prediction of Polymorphisms of DNA Repair Genes on the Efficacy of Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer: A Network Meta-Analysis. Journal of cellular biochemistry 2017 12 118 (12): 4782-4791. Yu Shao-Nan, Liu Gui-Feng, Li Xue-Feng, Fu Bao-Hong, Dong Li-Xin, Zhang Shu-H |
Clinical-pharmacogenetic models for personalized cancer treatment: application to malignant mesothelioma. Scientific reports 2017 Apr 7 46537. Gori?ar Katja, Kova? Viljem, Dolžan Vi |
Polymorphisms at microRNA binding sites of Ara-C and anthracyclines-metabolic pathway genes are associated with outcome of acute myeloid leukemia patients. Journal of translational medicine 2017 Nov 15 (1): 235. Cao Hai-Xia, Miao Chao-Feng, Yan Liang, Tang Ping, Zhang Li-Rong, Sun Li |
Clinical significance of UGT1A1 polymorphism and expression of ERCC1, BRCA1, TYMS, RRM1, TUBB3, STMN1 and TOP2A in gastric cancer. BMC gastroenterology 2017 1 17 (1): 2. Cao Yongkuan, Zhang Guohu, Wang Peihong, Zhou Jun, Gan Wei, Song Yaning, Huang Ling, Zhang Ya, Luo Guode, Gong Jiaqing, Zhang L |
Somatic FGFR3 Mutations Distinguish a Subgroup of Muscle-Invasive Bladder Cancers with Response to Neoadjuvant Chemotherapy. EBioMedicine 2018 Jun . Yang Zhao, Zhang Ruiyun, Ge Yunxia, Qin Xuying, Kang Xing, Wang Yue, Zhang Xu, Song Chengli, Quan Xiaofang, Wang Haifeng, Chen Haige, Li Cho |
Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patients. International journal of cancer 2019 9 146 (11): 3087-3097. Nikanjam Mina, Arguello David, Gatalica Zoran, Swensen Jeff, Barkauskas Donald A, Kurzrock Razel |
Association between certain non-small cell lung cancer driver mutations and predictive markers for chemotherapy or programmed death-ligand 1 inhibition. Cancer science 2019 Apr . Liang Wenhua, Guo Minzhang, Pan Zhenkui, Cai Xiuyu, Li Caichen, Zhao Yi, Liang Hengrui, Yang Haiying, Wang Zhen, Chen Wenting, Xu Chuhong, Yang Xinyun, Sun Jianyu, He Ping, Gu Xia, Yin Weiqiang, He Jianxi |
Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer. Cancer communications (London, England) 2019 Oct 39 (1): 57. Lin Shaoyan, Yue Jian, Guan Xiuwen, Yuan Peng, Wang Jiayu, Luo Yang, Fan Ying, Cai Ruigang, Li Qiao, Chen Shanshan, Zhang Pin, Li Qing, Ma Fei, Xu Bing |
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). ESMO open 2020 Dec 6 (1): 100019. Pellegrino B, Cavanna L, Boggiani D, Zamagni C, Frassoldati A, Schirone A, Caldara A, Rocca A, Gori S, Piacentini F, Berardi R, Brandes A A, Foglietta J, Villa F, Todeschini R, Tognetto M, Naldi N, Bortesi B, Montemurro F, Ardizzoni A, Boni L, Musolino |
6:2 Cl-PFESA, a proposed safe alternative for PFOS, diminishes the gemcitabine effectiveness in the treatment of pancreatic cancer. Journal of hazardous materials 2024 6 474 134790. Jiawei Hong, Keyi Du, Weichen Zhang, Junran Chen, Hangbiao Jin, Yuanchen Chen, Yifan Jiang, Hanxi Yu, Xiaoyu Weng, Shusen Zheng, Jun Yu, Linping C |
- Page last reviewed:Feb 1, 2024
- Content source: